Product Description
FPP003 is antibody-inducing peptide targeting interleukin-17A (IL-17A) under joint development with Osaka University and Sumitomo Dainippon Pharma.
Mechanisms of Action: IL17 Inducer
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FunPep Co
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619000599178 |
ACTRN12619000599178 | P2 |
Completed |
Psoriasis |
2022-06-06 |
2026-01-30 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|